Autoimmune hemolytic anemia (AIHA) is a process of the destruction of RBCs by anti-RBC autoantibodies. It is difficult to give a definite diagnosis and specific treatment for this condition. Especially, AIHA is a rare disease, which occurs at the same time as the infection [5, 6]. To our knowledge, there are only 4 case reports of malaria-induced AIHA. All cases were in children, and there was 1 young patient [2, 3, 4, 7]. Until now, there have been few cases of combined AIHA and identifiable autoantibodies in malaria patients. We also have inadequate data for using steroid (immunosuppressive medication) during malaria treatment. Our present case was in an adult patient with
A 43-year-old woman was admitted to hospital with high-grade fever for a week, chills and rigor, and vomiting, and then developing drowsiness. There was no history of orthopnea, paroxysmal nocturnal dyspnea, chest pain, syncope, or apparent bleeding. The patient had traveled to Myanmar and lived in a forest for 3 days. She was nonhypertensive and non-diabetic. Examination revealed pallor, icteric sclera, pulse rate of 114 beats/min, blood pressure of 90/56 mmHg, and body temperature of 38.3°C. Chest and cardiovascular system were normal. Abdominal examination showed palpable liver (liver span 14 cm) and no splenomegaly. Physical examination of central nervous system function was unremarkable. Blood investigations revealed the following: hemoglobin 11.6 g/ dL, white blood cell (WBC) count 9,000 cells/mm3, platelet count 105,000 cells/mm3, blood sugar 80 mg/dL, total bilirubin 6.6 mg/dL, direct bilirubin 6.3 mg/dL, aspartate transaminase 382 U/L, alanine transaminase 210 U/L, total protein 5.3 g/dL, albumin 2.6 g/dL, blood urea nitrogen 64.4 mg/dL (normal range 6–20 mg/dL), and serum creatinine 2.66 mg/dL (normal range 0.510–0.95 mg/dL). Peripheral blood smears showed normochromic and microspherocytic red cells, agglutination of RBCs, normal leukocytes, and malaria parasite (5-ring stage of
She received steroid (prednisolone) at 1 mg/kg bodyweight daily and supportive medication (omeprazole 20 mg/ day). Three days later, her blood was matched with 1 unit of leukocyte-poor packed RBCs, and no transfusion reaction occurred during transfusion. The patient showed marked improvement on the steroid treatment after 1 week. Her hemoglobin level became normal within 2 weeks. The patient was discharged on a tapering course of the steroid as an outpatient within a month. Her hemoglobin had increased to 13.9 g/dL within normal limits of peripheral blood smear, and a blood test for the malaria parasite found none after 1 month (
The present case report was approved by the Ethical Committee of Rajavithi Hospital (approval No. 229/2559). The patient has provided her written consent for the publication of this case report and any accompanying information and images.
+, positive; –, negative Arte, artesunate; BT, blood transfusion; CFTX, ceftriaxone; DAT, direct antiglobulin test; Pred, prednisolone
AIHA concomitant with malaria infection is a rare condition. AHIA can be classified on the basis of the temperature suitable for detecting autoantibody binding to RBC membranes into warm antibody (WA-AIHA), cold antibody (CA-AIHA), and biphasic antibody. This condition can be primary or secondary to lymphoproliferative disorders, autoimmune disorders, or hematological malignancy [9, 10]. Tropical infectious diseases related to AIHA are rare conditions and cause problems. History and clinical findings include pallor, dyspnea, jaundice, and laboratory investigations that are essential for demonstrating hemolysis conditions (high reticulocytosis, indirect hyperbilirubinemia, and LDH).
Our patient underwent clinical and laboratory investigations of her hemolytic condition during treatment for malaria. Her condition was compatible with severe falciparum infection because of renal impairment, algid malaria, and severe anemia [11]. Treatment of algid malaria was with the combination artesunate as an i.v. infusion and the rapid eradication of malaria parasite with a broad-spectrum antibiotic [11]. Afterward, her blood smear developed microspherocytes and clumping of RBCs, which were consistent with AIHA. The RBCs from this patient tested positive for DAT (positive for anti-IgG antisera). The majority of reported cases have been in young patients and children, which is contrary to our experience of a case in an adult patient. The predominant sex affected is female among the case reports. There was one patient with an autoimmune disorder (tested positive for ANA) [4]. The patient with an autoimmune disorder was investigated for the cause of warm-type AIHA (such as medication, autoimmune disorders, and lymphoproliferative disorders). For most patients with malaria, AIHA occurs during the second week after receiving treatment for malaria [2, 4, 7].
The blood of the present patient was screened and found positive for antibodies. We rechecked her history and found that she had neither a history of previous blood transfusion nor pregnancy. A blood sample was referred to a RBC reference laboratory of the Thai Red Cross Society according to BCSH guidelines [12]. The results revealed both autoanti-E and autoanti-I on RBCs. For her severe anemia symptoms, RBC transfusion with E-antigen-negative blood was indicated. We found no transfusion reaction for this compatible blood type. To our knowledge, our patient has the first reported case of a combination of AIHA and autoanti-E with autoanti-I in a malaria patient, and we postulate that these conditions were induced by
Specific treatments in this study and from the literature are summarized in
Summary of patients with malaria concomitant with autoimmune hemolytic anemia
Reference/ | Present | [2] | [3] | [4] | [7] | |||
---|---|---|---|---|---|---|---|---|
Characteristic | case (2016) | |||||||
Age (years) | 42 | 27 | 17 | 15 | 7 | 15 | 7 | |
Sex | Female | Male | Female | Female | Female | Female | Male | |
Presenting symptom | Fever | Fever | Fever | Fever | Fever | Fever | Fever | |
(7 days) | (2 days) | (7 days) | (4 days) | (7 days) | (14 days) | (3 days) | ||
Malaria infection | P.f | P.f | P.f | P.v. + P.f | P.v. + P.f | P.f | P.v | |
Anti-malarial | Artesunate | Antimalarial | Artemether/lumefantrine | Artesunate i.v | Artesunate | Artesunate i.v | Chloroquine | |
regimen (duration) | i.v. (7 days) | treatment | (6 days) and then artesunate | (5 days) | i.v. (5 days) + | (N/A) | (2 days) + primaquine | |
(unknown) | (2 days) | mefloquine | (14 days) | |||||
Other antibiotic | Ceftriaxone | N/A | Ceftriaxone, metronidazole | Ceftriaxone | Ceftriaxone | Ceftriaxone | NEG | |
treatment | gentamicin, piperacillin | doxycycline | ||||||
ciprofloxacin | ||||||||
Onset of AIHA (days | 12th | 1st | 14th | 9th | 7th | 11th | 2nd | |
after antimalarial | ||||||||
treatment) | ||||||||
Diagnostic method | ||||||||
Hemoglobin | 3.5 | Hct. 15.2% | 4.6 | 4.8 | 5.1 | 4.5 | 5.2 | |
(g/dL) | ||||||||
Coombs test | POS | NEG | POS | NEG | N/A | NEG | POS | |
LDH (U/L) | High | N/A | High | High | High | High | N/A | |
Identify cause | ||||||||
ANA | NEG | N/A | NEG | NEG | POS | NEG | N/A | |
CA test POS | CA test POS | |||||||
Antibody | Autoanti-E | N/A | N/A | N/A | N/A | N/A | Autoanti-I | |
identification | Autoanti-I | |||||||
Specific treatment | Predni | No | Methylprednisolone | Prednisolone | Prednisolone | Prednisolone | Prednisolone | |
for AIHA (dosage) | solone | (60 mg/day × 7 days) | (1 MKD) | (N/A) | (0.5 MKD) | (1 MKD) | ||
(1 MKD) | Prednisolone (1 MKD) | |||||||
PRC transfusion | 1 | 0 | 0 | 2 | 3 | 0 | 1 | |
(unit) | ||||||||
Duration of recovery | ||||||||
Malaria infection | 5 | N/A | N/A | N/A | 7 | 11 | 2 | |
(days) | ||||||||
AIHA, anemia (days) | 8 | 4 | 7 | 28 | 28 | 56 | 10 | |
Stop prednisolone | 30 | N/A | 60 | 42 | 28 | N/A | 56 | |
(days) |
AIHA, autoimmune hemolytic anemia; ANA, antinuclear antigen; CA, cold agglutinin; Hct., hematocrit; i.v., intravenously; LDH, lactate dehydrogenase; MKD, milligram per kilogram per day; N/A, no data available; NEG, negative; P.f.,
Thus, we recommended a short course of a standard dose of oral prednisolone treatment for severe anemic malaria with the evidence of AIHA. However, predicting factors for AIHA and autoantibodies in patients with malaria infection remain unclear and require more data to elucidate.